Update on cancer predisposition syndromes and surveillance guidelines for childhood brain tumors.


Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
04 Apr 2024
Historique:
accepted: 04 04 2024
received: 03 01 2024
revised: 27 02 2024
medline: 4 4 2024
pubmed: 4 4 2024
entrez: 4 4 2024
Statut: aheadofprint

Résumé

Tumors of the central nervous system (CNS) comprise the second most common group of neoplasms in childhood. The incidence of germline predisposition among children with brain tumors continues to grow as our knowledge on disease aetiology increases. Some children with brain tumors may present with non-malignant phenotypic features of specific syndromes (e.g. nevoid basal cell carcinoma syndrome, neurofibromatosis type 1 and type 2, DICER1 syndrome, and constitutional mismatch repair deficiency), while others may present with a strong family history of cancer (e.g. Li-Fraumeni syndrome), or with a rare tumor commonly found in the context of germline predisposition (e.g. rhabdoid tumor predisposition syndrome). Approximately 50% of patients with a brain tumor may be the first in a family identified to have a predisposition. The past decade has witnessed a rapid expansion in our molecular understanding of CNS tumors. A significant proportion of CNS tumors are now well characterized and known to harbor specific genetic changes that can be found in the germline. Additional novel predisposition syndromes are also being described. Identification of these germline syndromes in individual patients has not only enabled cascade testing of family members and early tumor surveillance but increasingly has also impacted cancer management in those patients. Therefore, the AACR Cancer Predisposition Working Group chose to highlight these advances in CNS tumor predisposition and summarize and/or generate surveillance recommendations for established and more recently emerging pediatric brain tumor predisposition syndromes.

Identifiants

pubmed: 38573059
pii: 742912
doi: 10.1158/1078-0432.CCR-23-4033
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Jordan R Hansford (JR)

Women's and Children's Hospital, North Adelaide, SA, Australia.

Anirban Das (A)

Hospital for Sick Children, Toronto, Canada.

Rose B McGee (RB)

St. Jude Children's Research Hospital, Memphis, TN, United States.

Yoshiko Nakano (Y)

Hospital for Sick Children, Toronto, Ontario, Canada.

Jack Brzezinski (J)

Hospital for Sick Children, Toronto, Canada.

Sarah R Scollon (SR)

Baylor College of Medicine, Houston, TX, United States.

Surya P Rednam (SP)

Baylor College of Medicine, Houston, tx, United States.

Jaclyn Schienda (J)

Dana-Farber Cancer Institute, United States.

Orli Michaeli (O)

Schneider Children's Medical Center of Israel, Patach Tikva, Israel.

Sun Young Kim (SY)

Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.

Mary-Louise C Greer (MC)

Hospital for Sick Children, Toronto, Ontario, Canada.

Rosanna Weksberg (R)

Hospital for Sick Children, Toronto, State, Canada.

Douglas R Stewart (DR)

National Cancer Institute, Bethesda, MD, United States.

William D Foulkes (WD)

McGill University, Montreal, Quebec, Canada.

Uri Tabori (U)

Hospital for Sick Children, Toronto, Ontario, Canada.

Kristian W Pajtler (KW)

German Cancer Research Center, Heidelberg, Germany.

Stefan M Pfister (SM)

Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany.

Garrett M Brodeur (GM)

Children's Hospital of Philadelphia, Philadelphia, PA, United States.

Junne Kamihara (J)

Dana-Farber Cancer Institute, Boston, MA, United States.

Classifications MeSH